CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 77 enrolled
Drug / intervention
Cardiac Resynchronization Therapy - Defibrillator (CRT-D)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00626093
NCT00626093Phase 4Completed
CompareCT.gov

Effect of Cardiac Resynchronization Therapy (CRT) on the Defibrillation Threshold (DFT) Estimates

Abbott Medical Devices·interventional·Posted Feb 29, 2008·Updated Feb 5, 2019

In Brief

A Phase 4 clinical trial evaluating Cardiac Resynchronization Therapy - Defibrillator (CRT-D) for Sudden Cardiac Death. Completed, enrolled 77 participants across 2 sites.

Detailed Summary

The purpose of this prospective study is to evaluate the effect of cardiac resynchronization therapy (CRT) on the defibrillation threshold (DFT) estimates in cardiac resynchronization therapy defibrillators (CRT-D) patients. The hypothesis of the study is that defibrillation threshold (DFT) will decrease with 6 months of cardiac resynchronization therapy (CRT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSudden Cardiac Death
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 29, 2008
Enrollment StartJan 1, 2008
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.3 years ago

Interventions

Cardiac Resynchronization Therapy - Defibrillator (CRT-D)device

* Patients in the study who receive Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for Cardiac Resynchronization Therapy (CRT). * Patient undergoes Defibrillation threshold (DFT) testing at implant and at 6 months. Defibrillation threshold (DFT) testing will include 3 ventricular fibrillation (VF) inductions.